OA10502A - Indole derivatives as 5-ht receptor antagonist - Google Patents

Indole derivatives as 5-ht receptor antagonist Download PDF

Info

Publication number
OA10502A
OA10502A OA70058A OA70058A OA10502A OA 10502 A OA10502 A OA 10502A OA 70058 A OA70058 A OA 70058A OA 70058 A OA70058 A OA 70058A OA 10502 A OA10502 A OA 10502A
Authority
OA
OAPI
Prior art keywords
methoxy
pyrid
pyridyl
phenyl
trifluoromethyl
Prior art date
Application number
OA70058A
Other languages
English (en)
Inventor
Laramie Mary Gaster
Paul Adrian Wyman
Keith Raymond Mulholland
David Thomas Davies
David Malcolm Duckworth
Ian Thomson Forbes
Graham Elgin Jones
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9502052.5A external-priority patent/GB9502052D0/en
Priority claimed from GBGB9508327.5A external-priority patent/GB9508327D0/en
Priority claimed from GBGB9508967.8A external-priority patent/GB9508967D0/en
Priority claimed from GBGB9516845.6A external-priority patent/GB9516845D0/en
Priority claimed from GBGB9517542.8A external-priority patent/GB9517542D0/en
Priority claimed from GBGB9518574.0A external-priority patent/GB9518574D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA10502A publication Critical patent/OA10502A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
OA70058A 1995-02-02 1997-08-01 Indole derivatives as 5-ht receptor antagonist OA10502A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9502052.5A GB9502052D0 (en) 1995-02-02 1995-02-02 Novel compounds
GBGB9508327.5A GB9508327D0 (en) 1995-04-25 1995-04-25 Novel compounds
GBGB9508967.8A GB9508967D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9516845.6A GB9516845D0 (en) 1995-08-17 1995-08-17 Novel compounds
GBGB9517542.8A GB9517542D0 (en) 1995-08-26 1995-08-26 Novel compounds
GBGB9518574.0A GB9518574D0 (en) 1995-09-12 1995-09-12 Novel compounds

Publications (1)

Publication Number Publication Date
OA10502A true OA10502A (en) 2002-04-12

Family

ID=27547235

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70058A OA10502A (en) 1995-02-02 1997-08-01 Indole derivatives as 5-ht receptor antagonist

Country Status (34)

Country Link
US (3) US5990133A (de)
EP (1) EP0808312B1 (de)
JP (1) JPH10513442A (de)
KR (1) KR19980701879A (de)
CN (1) CN1151147C (de)
AP (1) AP657A (de)
AR (1) AR002705A1 (de)
AT (1) ATE197300T1 (de)
AU (1) AU699727B2 (de)
BG (1) BG101806A (de)
BR (1) BR9607016A (de)
CA (1) CA2212061A1 (de)
CZ (1) CZ294097B6 (de)
DE (1) DE69610822T2 (de)
DK (1) DK0808312T3 (de)
EA (1) EA000304B1 (de)
ES (1) ES2151652T3 (de)
FI (1) FI973205A (de)
GR (1) GR3035075T3 (de)
HK (1) HK1003883A1 (de)
HU (1) HU223601B1 (de)
IL (1) IL116998A (de)
MA (1) MA23792A1 (de)
MY (1) MY132229A (de)
NO (1) NO313520B1 (de)
NZ (1) NZ301265A (de)
OA (1) OA10502A (de)
PL (1) PL184490B1 (de)
PT (1) PT808312E (de)
RO (1) RO115522B1 (de)
SI (1) SI0808312T1 (de)
SK (1) SK103897A3 (de)
TR (1) TR199700749T1 (de)
WO (1) WO1996023783A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2151652T3 (es) * 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9612885D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6541209B1 (en) 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420541B1 (en) 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9710523D0 (en) * 1997-05-23 1997-07-16 Smithkline Beecham Plc Novel compounds
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999043650A2 (en) * 1998-02-25 1999-09-02 Smithkline Beecham Plc Process(es) for the preparation of 6-trifluoromethyl-indoline derivatives
CA2325559A1 (en) * 1998-04-14 1999-10-21 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2378243C (en) * 1999-08-04 2012-05-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
AUPQ319899A0 (en) 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001241128A1 (en) * 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
FR2807754A1 (fr) * 2000-04-13 2001-10-19 Adir Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
GB2380190A (en) * 2001-08-28 2003-04-02 Bayer Ag Antiinflammatory heterocyclic sulphones
AU2002362426B2 (en) 2001-09-29 2008-09-11 Lg Electronics Inc. Method for transferring and/or receiving data in communication system and apparatus thereof
US7071213B2 (en) 2001-11-14 2006-07-04 Schering Corporation Cannabinoid receptor ligands
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
WO2004000807A1 (en) 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
WO2004004720A1 (en) * 2002-07-03 2004-01-15 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
NZ537980A (en) * 2002-08-23 2007-08-31 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing HCV infection
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1558586B1 (de) 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Hemmer der akt aktivität
US20060194825A1 (en) * 2002-12-20 2006-08-31 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2004058683A2 (en) * 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
AU2003297441A1 (en) * 2002-12-24 2004-07-22 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
EP1631546A1 (de) * 2003-04-25 2006-03-08 H. Lundbeck A/S Substituierte indolin- und indolderivate
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
ATE548353T1 (de) * 2004-03-23 2012-03-15 Arena Pharm Inc Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
KR20140048343A (ko) * 2004-09-02 2014-04-23 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2006078610A1 (en) * 2005-01-19 2006-07-27 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
WO2007026920A2 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
WO2007054257A2 (en) 2005-11-08 2007-05-18 Laboratorios Del Dr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
CA2646081C (en) 2006-05-18 2017-06-27 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CA2654898A1 (en) * 2006-07-07 2008-10-01 Boehringer Ingelheim International Gmbh New chemical compounds
EP1884515A1 (de) 2006-07-31 2008-02-06 Laboratorios del Dr. Esteve S.A. Substituierte Indanylsulfonamid-Verbindungen, ihre Herstellung und Verwendung als Medikament
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
ATE499099T1 (de) 2007-07-19 2011-03-15 Esteve Labor Dr Substituierte tetrahydro- chinolinsulfonamidverbindungen, ihre herstellung und ihre verwendung als medikamente
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
PT2364142T (pt) 2008-10-28 2018-04-23 Arena Pharm Inc Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
KR20110114664A (ko) 2009-01-16 2011-10-19 메사추세츠 인스티튜트 오브 테크놀로지 자폐 스펙트럼 장애의 진단 및 치료
DK2477629T3 (en) * 2009-09-17 2016-08-22 Univ Vanderbilt SUBSTITUTED HETEROARYLAMIDANALOGER AS mGluR5 allosteric modulators NEGATIVE AND METHODS OF MAKING AND USE THEREOF
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2552907B1 (de) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazole
EP2552905B1 (de) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibitoren der B-Raf Kinase
US9751847B2 (en) 2010-10-14 2017-09-05 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
KR101972619B1 (ko) * 2011-09-29 2019-04-25 오노 야꾸힝 고교 가부시키가이샤 페닐 유도체
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
WO2013052845A1 (en) 2011-10-05 2013-04-11 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
EP3071568A1 (de) 2013-11-19 2016-09-28 Vanderbilt University Substituierte imidazopyridin- und triazolopyridinverbindungen als negative allosterische modulatoren von mglur5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
EP3419980A4 (de) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University Pi-kinase-inhibitoren mit anti-infektiver aktivität
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
MX2024007221A (es) * 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos.
WO2023114325A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Constrained amine psychoplastogens and uses thereof
IL313457A (en) * 2021-12-15 2024-08-01 Delix Therapeutics Inc Compressed pyrrolidine psychoplastogens and their uses
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE581862A (de) * 1958-08-22
SE370866B (de) * 1968-03-21 1974-11-04 Ciba Geigy Ag
JPH06500551A (ja) * 1990-09-13 1994-01-20 ビーチャム・グループ・パブリック・リミテッド・カンパニー ５ｈｔ受容体アンタゴニストとしてのインドールウレア
AU4704693A (en) * 1992-08-20 1994-03-15 Smithkline Beecham Plc Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
GB9306460D0 (en) * 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
ES2151652T3 (es) * 1995-02-02 2001-01-01 Smithkline Beecham Plc Derivados de indol como antagonistas del receptor 5ht.

Also Published As

Publication number Publication date
US5990133A (en) 1999-11-23
HUP9901115A3 (en) 2000-02-28
GR3035075T3 (en) 2001-03-30
ES2151652T3 (es) 2001-01-01
RO115522B1 (ro) 2000-03-30
HK1003883A1 (en) 1998-11-13
ATE197300T1 (de) 2000-11-15
HUP9901115A2 (hu) 1999-07-28
DK0808312T3 (da) 2001-02-12
FI973205A (fi) 1997-10-01
CZ244597A3 (cs) 1998-09-16
IL116998A0 (en) 1996-09-12
TR199700749T1 (xx) 1998-02-21
CZ294097B6 (cs) 2004-10-13
DE69610822D1 (de) 2000-12-07
DE69610822T2 (de) 2001-06-07
IL116998A (en) 2001-08-08
MY132229A (en) 2007-09-28
KR19980701879A (ko) 1998-06-25
CA2212061A1 (en) 1996-08-08
CN1151147C (zh) 2004-05-26
BR9607016A (pt) 1997-10-28
AP9701036A0 (en) 1997-07-31
AU699727B2 (en) 1998-12-10
EP0808312A1 (de) 1997-11-26
EA199700156A1 (ru) 1997-12-30
EP0808312B1 (de) 2000-11-02
EA000304B1 (ru) 1999-04-29
NZ301265A (en) 1998-12-23
MA23792A1 (fr) 1996-10-01
US20030105139A1 (en) 2003-06-05
SI0808312T1 (de) 2001-02-28
US6235758B1 (en) 2001-05-22
JPH10513442A (ja) 1998-12-22
AP657A (en) 1998-08-06
AR002705A1 (es) 1998-04-29
AU4664696A (en) 1996-08-21
US6638953B2 (en) 2003-10-28
NO973543D0 (no) 1997-08-01
FI973205A0 (fi) 1997-08-01
PL321706A1 (en) 1997-12-22
NO313520B1 (no) 2002-10-14
WO1996023783A1 (en) 1996-08-08
SK103897A3 (en) 1998-02-04
BG101806A (en) 1998-04-30
PL184490B1 (pl) 2002-11-29
HU223601B1 (hu) 2004-10-28
CN1179156A (zh) 1998-04-15
NO973543L (no) 1997-10-01
PT808312E (pt) 2001-03-30

Similar Documents

Publication Publication Date Title
OA10502A (en) Indole derivatives as 5-ht receptor antagonist
TWI628176B (zh) 蛋白質激酶抑制劑
US7504401B2 (en) Anti-cancer agents and uses thereof
WO2021050915A1 (en) Mta-cooperative prmt5 inhibitors
US20080280891A1 (en) Anti-cancer agents and uses thereof
KR20070114123A (ko) 염증 치료에 유용한 인돌
US7906533B2 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2005095384A1 (en) Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
TW200526620A (en) Pyrazine derivatives and pharmaceutical use thereof
EP1807416B1 (de) Nicotinamidpyridinharnstoffe als Kinaseinhibitoren vaskulärer Endothelwachstumsfaktorrezeptoren
WO2010096722A1 (en) 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
OA10944A (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
MXPA97005992A (en) Indol derivatives as receptor antagonists5